PTC Therapeutics announced a $500 million private placement of zero-coupon convertible senior notes due 2031, with a conversion price set at $107.48 per share, representing a 40% premium over the June 15, 2026 closing price. The proceeds will primarily be used to repurchase or repay $222 million of its 1.5% convertible notes maturing in 2026, helping to refinance existing debt. The new notes do not bear interest and mature in 2031, with conversion rights starting in 2031 under specified conditions. This refinancing move aims to optimize PTC's capital structure and provide financial flexibility for general corporate purposes.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
